Neurocrine Biosciences, Inc. Appoints David-Alexandre 'DA' Gros M.D. as President and Chief Operating Officer
January 06, 2017 at 01:30 pm
Share
Neurocrine Biosciences, Inc. announced that David-Alexandre 'DA' Gros M.D. has joined the executive management team as President and Chief Operating Officer. Dr. Gros has extensive experience in developing and executing bio-pharmaceutical growth strategies. He joins Neurocrine from Alnylam Pharmaceuticals where he served as Senior Vice President, Chief Business Officer and was a member of the Management Board. His responsibilities included strategy, finance, business development, communications, investor relations, and shared services. Prior to Alnylam, as Executive Vice President and Chief Strategy Officer at Sanofi, where he was a member of the Executive Committee, Dr. Gros' responsibilities included corporate strategy, business development and licensing, mergers and acquisitions, alliance management, and structured investments, including the corporate venture fund which he re-launched. Before Sanofi, Dr. Gros
held management positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.